
Ke ʻimi nei i ka lapaʻau kūpono no genetic mutation lung cancer hiki ke kaumaha. Kōkua kēia alakaʻi piha iā ʻoe e hoʻomaopopo i kāu mau koho a huli i kahi mālama kūikawā kokoke iā ʻoe. E ʻimi mākou i nā ala lapaʻau like ʻole i hoʻohālikelike ʻia i nā hoʻololi genetic kikoʻī, wehewehe i ke koʻikoʻi o ka lāʻau lapaʻau pilikino, a hāʻawi i nā kumuwaiwai e ʻimi ai i nā oncologists alakaʻi a me nā keʻena noiʻi ma kou wahi.
He maʻi paʻakikī ka maʻi ʻaʻai māmā, a ʻo ka loaʻa ʻana o nā hoʻololi genetic kikoʻī e hoʻoikaika nui i nā hoʻolālā lapaʻau. Hoʻopili kēia mau hoʻololi i ka ulu ʻana o nā maʻi kanesa a pane i nā lāʻau lapaʻau. He mea koʻikoʻi ka hoʻomaopopo ʻana i ka mutation kikoʻī e alakaʻi nei i kāu maʻi kanesa no ka hoʻolālā lapaʻau pilikino. ʻO nā hoʻololi maʻamau ka EGFR, ALK, ROS1, BRAF, a me nā mea ʻē aʻe. ʻOkoʻa nā koho lapaʻau ma muli o ka mutation i ʻike ʻia. No ka laʻana, hiki i nā poʻe maʻi me nā hoʻololi EGFR ke pōmaikaʻi mai nā lāʻau lapaʻau e like me tyrosine kinase inhibitors (TKIs).
He mea nui ka hoʻāʻo ʻana no ka hoʻoholo ʻana i nā hoʻololi genetic kikoʻī i loaʻa i loko o kāu mau maʻi maʻi kanesa. Hoʻopili maʻamau kēia i kahi biopsy, kahi e nānā ʻia ai kahi ʻāpana liʻiliʻi o ka ʻiʻo tumo. Aia kekahi mau ʻano hana, e komo pū ana me ka hanauna hou aku (NGS), hiki ke ʻike i kahi ākea o nā mutations i ka manawa like. Na kāu kauka oncologist e alakaʻi iā ʻoe ma ke kaʻina hoʻāʻo kūpono a wehewehe i nā hopena.
Lapaʻau no genetic mutation lung cancer pili pinepine i ka hui pū ʻana o nā lāʻau lapaʻau i kūpono i ka mutation kikoʻī. Hiki i kēia mau mea ke komo:
Kuhi ʻia nā lāʻau lapaʻau i hoʻopaʻa ʻia i nā protein abnormal i hana ʻia e nā maʻi maʻi maʻi ma muli o nā hoʻololi genetic. ʻOi aku ka maikaʻi o kēia mau lāʻau lapaʻau a ʻoi aku ka liʻiliʻi o nā hopena ʻaoʻao ma mua o ka chemotherapy maʻamau. Loaʻa nā TKI e like me afatinib, gefitinib, a me erlotinib no nā hoʻololi EGFR, a me crizotinib a i ʻole alectinib no nā hoʻololi ALK. E kōkua kāu kauka oncologist iā ʻoe e hoʻomaopopo i ke ʻano o ka lāʻau lapaʻau i kūpono no kāu mutation kikoʻī.
Hoʻohana ʻo Immunotherapy i ka ʻōnaehana pale o kou kino e hakakā ai i nā maʻi maʻi maʻi. Hiki i kēia mau lāʻau lapaʻau ke hana maikaʻi loa i kekahi mau ʻano subtypes o ka maʻi maʻi ʻaʻai māmā. Hoʻohana mau ʻia nā lāʻau lapaʻau immunotherapy e like me pembrolizumab a me nivolumab.
ʻOiai ʻoi aku ka maikaʻi o ka lāʻau lapaʻau a me ka immunotherapy no ka hoʻololi ʻana o nā genetic, he koho koʻikoʻi ka chemotherapy, ʻoi aku ka hui pū ʻana me nā lāʻau lapaʻau ʻē aʻe a i ʻole no ka mālama ʻana i nā maʻi holomua. E hoʻoholo ana kāu kauka oncologist i ka regimen chemotherapy kūpono loa e pili ana i kāu kūlana kikoʻī.
Hoʻohana ka lāʻau lapaʻau i ka pāhawewe ikaika nui e pepehi i nā maʻi maʻi maʻi. Hoʻohana pinepine ʻia i ka hui pū ʻana me nā lāʻau lapaʻau ʻē aʻe a i ʻole e hoʻēmi i nā hōʻailona ma nā pae holomua.
Ke ʻimi nei i nā poʻe loea oncologists a me nā kikowaena lapaʻau kūikawā genetic mutation lung cancer koʻikoʻi. E hoʻomaka me ka nīnau ʻana i kāu kauka mālama mua, nāna e kuhikuhi iā ʻoe i kahi oncologist. Hiki iā ʻoe ke ʻimi ma ka pūnaewele no nā oncologists a me nā kikowaena maʻi kanesa kokoke iā ʻoe. Nui nā halemai a me nā keʻena noiʻi i hoʻolaʻa i nā papahana maʻi maʻi ʻōpū me ka loea i ka hoʻāʻo genetic a me ka mālama pilikino. E noʻonoʻo e nānā i nā pilina me nā hui noiʻi maʻi maʻi e like me ka National Cancer Institute (NCI). ʻO ka Shandong Baofa Cancer Research Institute He keʻena alakaʻi e hāʻawi ana i nā lāʻau lapaʻau kiʻekiʻe a me ka noiʻi ʻana i ka oncology.
ʻO ka ʻike i hāʻawi ʻia ma ʻaneʻi no ka ʻike ākea a me nā kumu ʻike wale nō, ʻaʻole ia he ʻōlelo aʻoaʻo olakino. E kamaʻilio mau me kāu kauka a i ʻole kekahi mea lawelawe olakino kūpono me nā nīnau āu e pili ana i kahi maʻi olakino. Mai hoʻowahāwahā i ka ʻōlelo aʻo lapaʻau ʻoihana a i ʻole e hoʻopaneʻe i ka ʻimi ʻana ma muli o kahi mea āu i heluhelu ai ma kēia pūnaewele.
| ʻAno hoʻololi | Nā Koho Lapaʻau Kūlohelohe |
|---|---|
| EGFR | Afatinib, Gefitinib, Erlotinib, Osimertinib |
| ALK | Crizotinib, Alectinib, Brigatinib |
| ROS1 | Crizotinib, Lorlatinib, Entrectinib |
Hōʻole: Ua manaʻo ʻia kēia ʻike no nā kumu hoʻonaʻauao wale nō a ʻaʻole pono e manaʻo ʻia he ʻōlelo aʻoaʻo olakino. E kūkākūkā mau me kekahi ʻoihana mālama ola kūpono no ka hōʻoia ʻana a me ka mālama ʻana i kekahi maʻi olakino.
Nā Puna: [E hoʻokomo i nā loulou i nā kumu hilinaʻi e like me NCI, nā moʻolelo puke pai e pili ana, a pēlā aku, me rel=nofollow]